Advertisement
Advertisement
As of 01:08PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 519.36 |
| Open | 518.32 |
| Bid | 514.67 x 900 |
| Ask | 516.79 x 800 |
| Day's Range | 514.59 - 524.27 |
| 52 Week Range | 430.16 - 539.13 |
| Volume | |
| Avg. Volume | 74,220 |
| Market Cap | 7.703B |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | 31.60 |
| EPS (TTM) | 16.31 |
| Earnings Date | Apr 24, 2023 - Apr 28, 2023 |
| Forward Dividend & Yield | 1.52 (0.29%) |
| Ex-Dividend Date | Feb 24, 2023 |
| 1y Target Est | 579.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-10% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for CHE
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Chemed CorpCHE: Raising target price to $539.00CHEMED CORP has an Investment Rating of HOLD; a target price of $539.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat8 days agoArgus Research
- Zacks
4 Promising Stocks From a Challenging Outpatient Home Health Industry
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.
- Zacks
Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions
Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.
- Zacks
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
